French medtech startup based in Bordeaux, developing AI-powered proteomic diagnostic tests to guide cancer treatment decisions.
Our first product targets advanced hepatocellular carcinoma (HCC), predicting individual patient response to available therapies.
Spun out from CHU Bordeaux and INSERM/CNRS (BRIC unit).
- Proteomic profiling of advanced hepatocellular carcinoma identifies predictive signatures of response to treatments — Delamarre et al., 2025, bioRxiv
